Treatment with TF-3 resulted in a reduction of number of activated osteoclasts, a higher bone mass, and protection against bone loss, suggesting that the inhibition of Dnmt3a could be a beneficial strategy for preventing bone loss and controlling postmenopausal osteoporosis. Here, DNMT3A is linked to postmenopausal osteoporosis.